ADTX (Aditxt) Growth Rank : 0 (As of Dec. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aditxt Growth Rank?

Aditxt has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Aditxt Growth Rank Related Terms

Thank you for viewing the detailed overview of Aditxt's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Aditxt Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219

Website

https://www.aditxt.com

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

Executives

Charles Athle Nelson	director	11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp	10 percent owner	787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes	officer: Chief Legal Officer and GC	737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung	director	1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley	officer: PRINCIPAL ACCOUNTING OFFICER	2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge	director	C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna	officer: CHIEF OPERATING OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne	officer: CHIEF FINANCIAL OFFICER	BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony	director	LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna	director, officer: CHIEF EXECUTIVE OFFICER	871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang	director, officer: CHIEF INNOVATION OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354